# Epicardial Delivery of XC001 Gene Therapy to Promote Angiogenesis in CAD Patients Undergoing Treatment With CABG

Study · id `cardio:ct-nct07118449` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07118449](<https://clinicaltrials.gov/study/NCT07118449>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT07118449

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 116 participants.

## Technical summary

Registry record NCT07118449. Randomized; quadruple masking; primary purpose treatment. Start 2025-08-27 (anticipated); primary completion 2026-12-30 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 116 participants (planned count; ClinicalTrials.gov record NCT07118449, source copy `cardio:ctgov-nct07118449-2025-08-12`, retrieved 2026-10-26)
- Planned start: 2025-08-27 (anticipated) (ClinicalTrials.gov record NCT07118449, source copy `cardio:ctgov-nct07118449-2025-08-12`, retrieved 2026-10-26)
- Primary completion: 2026-12-30 (anticipated) (ClinicalTrials.gov record NCT07118449, source copy `cardio:ctgov-nct07118449-2025-08-12`, retrieved 2026-10-26)
- Completion: 2027-06-30 (anticipated) (ClinicalTrials.gov record NCT07118449, source copy `cardio:ctgov-nct07118449-2025-08-12`, retrieved 2026-10-26)
- Countries: United States (ClinicalTrials.gov record NCT07118449, source copy `cardio:ctgov-nct07118449-2025-08-12`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "NOT\_YET\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07118449-2025-08-12`, retrieved 2026-10-26)

## The registry's words

- Brief title: Epicardial Delivery of XC001 Gene Therapy to Promote Angiogenesis in CAD Patients Undergoing Treatment With CABG
- Acronym: EXACT-CABG
- Condition: Coronary Artery Disease (CAD)
- Intervention (Drug): XC001
- Intervention (Drug): A195/placebo
- Lead sponsor: XyloCor Therapeutics, Inc.
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Coronary artery disease (`cardio:coronary-artery-disease`)

## Provenance

Content hash: 76c96f2563d8476bafcd22c9972de35345c8e71fffc71d4337cf659a2f0adc6b
Last substantive edit: 2026-10-26
Evidence last checked: Not recorded
